RxDoctor Payments DataLook up a doctor →

Reginald Fowler, MD

Critical Care Medicine · Winston-Salem, NCNPI 1386626240

Payments from drug & device makers

$1,418,107in general payments, 2019–2025

Across 540 payments — averaging $2626.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$421K
  • Sanofi US Services Inc.$339K
  • AstraZeneca$301K
  • E.r. Squibb & Sons, L.L.C.$257K
  • Boehringer Ingelheim International GmbH$46K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$23K
  • plus $30K from 37 others
$1,714in research payments, 2019–2025

Across 12 payments — averaging $142.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$2K

What the payments were for

  • Travel & lodging$732%
  • Food & beverage$3,35898%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,418,107 in reported general payments places this provider in the 95th percentile of 190 critical care medicine providers in North Carolina.

See all critical care medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$130,482
Medicare patients
599
Services billed
2,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter223$168,506
Breztri AerosphereBudesonide/Glycopyr/Formoterol146$115,525
Spiriva RespimatTiotropium Bromide55$34,205
SymbicortBudesonide/Formoterol Fumarate108$32,791
Breo ElliptaFluticasone/Vilanterol78$30,814
Stiolto RespimatTiotropium Br/Olodaterol Hcl41$25,375
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$21,625
Advair HfaFluticasone Propion/Salmeterol34$16,056
Ambrisentan12$15,154
Spiriva HandihalerTiotropium Bromide25$13,417
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate44$10,313
Albuterol Sulfate HfaAlbuterol Sulfate328$10,155
Wixela InhubFluticasone Propion/Salmeterol41$7,225
Incruse ElliptaUmeclidinium Bromide20$6,969
XareltoRivaroxaban12$6,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$676$233,368378 claims
AstraZenecaBreztri Aerosphere, Symbicort$301,399$148,317254 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$420,801$59,57996 claims
Johnson & JohnsonXarelto$13$6,47812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 190 critical care medicine providers in North Carolina.

Other critical care medicine in Winston-Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →